📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
53 announcements match the current filters (relevance ≥ 5).
Sun Pharma Sets July 7 as Record Date for ₹5 Final Dividend for FY 2025-26
Sun Pharmaceutical Industries Limited has declared a final dividend of ₹5 per equity share for the financial year 2025-26. The company has fixed July 7, 2026, as the record date to determine shareholder eligibility for the payout. The dividend is subject to approval at the 34th Annual General Meeting scheduled for July 31, 2026. Once approved, the payment will be processed on or before August 7, 2026.
Key Highlights
Final dividend of ₹5 per equity share announced for the financial year 2025-26.
Record date for dividend entitlement is fixed as Tuesday, July 7, 2026.
The 34th Annual General Meeting (AGM) will be held on July 31, 2026, at 4:00 p.m. IST.
Dividend payment will be completed by August 7, 2026, following shareholder approval.
TDS-related documents must be submitted by the record date of July 7, 2026.
👀 What to Watch
Investors should ensure they hold shares before the ex-dividend date to be eligible for the ₹5 payout. Shareholders should also update their tax residency certificates or relevant TDS documents with the RTA by July 7 to ensure appropriate tax treatment.
Sun Pharma Announces ₹5 Final Dividend; Record Date Set for July 7, 2026
Sun Pharmaceutical Industries has scheduled its 34th Annual General Meeting for July 31, 2026. The company has declared a final dividend of ₹5 per equity share for the financial year 2025-26. To be eligible for this payout, investors must hold the shares by the record date of July 7, 2026. The dividend is expected to be paid to shareholders on or before August 7, 2026, following approval at the AGM.
Key Highlights
Final dividend of ₹5 per equity share declared for the financial year 2025-26.
Record date for determining dividend eligibility is fixed as Tuesday, July 7, 2026.
The 34th Annual General Meeting (AGM) is scheduled for July 31, 2026, via Video Conferencing.
Dividend payment will be completed on or before August 7, 2026, subject to shareholder approval.
Deadline for submitting TDS-related documents is July 7, 2026.
👀 What to Watch
Investors interested in the dividend should ensure they own the stock before the ex-dividend date. Additionally, shareholders should update their bank details and submit tax-related documents by July 7 to ensure smooth credit and appropriate tax treatment.
Sun Pharma Q4 FY26: Revenue Up 13.6%, US Innovative Portfolio Crosses $1 Billion Milestone
Sun Pharma reported a 13.6% YoY revenue growth in Q4 FY26 to INR 14,559 crore, driven by strong performance in India and Global Innovative Medicine. While EBITDA margins contracted to 27.1% due to higher US spends and lower milestone income, the full-year EBITDA margin remained healthy at 30.3%. A key milestone was achieved as the US Innovative Medicine business crossed $1 billion for the first time, now surpassing the generic business in that region. The company has guided for high single-digit top-line growth in FY27 and expects to complete the Organon acquisition by Q4 FY27.
Key Highlights
Consolidated Q4 sales grew 13.6% YoY to INR 1,45,598 million, with full-year sales reaching INR 582 billion.
Global Innovative Medicine sales grew 20.1% in Q4 to $354 million, led by Ilumya, Cequa, and Winlevi.
India formulation sales grew 14.8% in Q4, outperforming the market with a 6% volume growth versus IPM's 1.6%.
US Innovative portfolio crossed $1 billion in FY26, becoming larger than the US generic business.
Total dividend for FY26 declared at INR 16 per share, including a final dividend of INR 5 per share.
👀 What to Watch
Investors should view the growth in the high-margin specialty/innovative portfolio as a long-term value driver that offsets generic pricing pressure. Monitor the integration of the Organon acquisition in FY27 as it will be a significant catalyst for future growth.
Sun Pharma Reports 50% Response Rate in Long-Term UNLOXCYT Study for Skin Cancer
Sun Pharma announced positive long-term follow-up data for UNLOXCYT (cosibelimab-ipdl) in treating locally advanced cutaneous squamous cell carcinoma (laCSCC). The study demonstrated a 50% objective response rate, with 27% of patients achieving a complete response. Crucially, the median duration of response has not been reached after a 31-month follow-up period, indicating high durability. Safety data remained favorable, with only 2% of patients experiencing severe immune-related adverse events.
Key Highlights
Objective response rate of 50% observed in 64 patients, with 27% achieving a complete response
Median duration of response not yet reached after more than 2.5 years (31 months) of follow-up
Strong safety profile with only 1 patient (2%) experiencing Grade 3 or higher immune-related adverse events
Represents the second largest prospective study for laCSCC patients treated with PD-(L)1 monotherapy
Specialty medicines portfolio, including oncology, currently accounts for approximately 20% of total company sales
👀 What to Watch
Investors should view this as a positive development for Sun Pharma's high-margin specialty portfolio, which is a key growth driver. The durable efficacy and safety profile of UNLOXCYT strengthen its competitive position in the global oncology market.
Sun Pharma Recommends ₹5 Final Dividend; FY26 Standalone Net Profit at ₹26,234 Million
Sun Pharmaceutical Industries has recommended a final dividend of ₹5 per equity share for FY 2025-26, pending shareholder approval. On a standalone basis, the company reported a revenue of ₹2,07,546.4 million for the full year, a decline from ₹2,29,774.0 million in the previous fiscal. Net profit for the year also decreased to ₹26,234.2 million compared to ₹42,280.8 million in FY25. Despite the earnings dip, the company increased its R&D investment to ₹21,635.0 million, indicating a focus on long-term product development.
Key Highlights
Recommended final dividend of ₹5 per equity share of face value ₹1 for FY 2025-26.
Standalone FY26 Revenue from Operations stood at ₹2,07,546.4 million, down ~9.7% YoY.
Standalone Net Profit for FY26 fell to ₹26,234.2 million from ₹42,280.8 million in FY25.
R&D expenses increased to ₹21,635.0 million, up from ₹19,226.2 million in the previous year.
Standalone Basic and Diluted EPS for the full year FY26 reported at ₹10.9.
👀 What to Watch
Investors should weigh the steady dividend payout against the decline in standalone profitability and monitor consolidated results for a comprehensive view of global performance. The rising R&D expenditure suggests a commitment to future growth through innovation.
Sun Pharma Q4 FY26 Standalone PAT Drops to ₹608.7 Cr; Recommends ₹5 Final Dividend
Sun Pharmaceutical Industries reported a standalone profit after tax of ₹6,087 million for Q4 FY26, a sharp decline from ₹20,419.7 million in the same quarter last year. For the full year FY26, standalone revenue from operations stood at ₹207,546.4 million, down from ₹229,774 million in FY25. Despite the lower earnings, the Board has recommended a final dividend of ₹5 per share. The annual results were impacted by exceptional items totaling ₹5,463.4 million.
Key Highlights
Recommended a final dividend of ₹5 per equity share of face value ₹1 for FY 2025-26.
Standalone Q4 FY26 revenue from operations decreased to ₹49,238.8 million from ₹71,794.5 million YoY.
Full-year standalone profit after tax fell to ₹26,234.2 million in FY26 compared to ₹42,280.8 million in FY25.
Research and Development (R&D) expenses for FY26 increased to ₹21,635.0 million from ₹19,226.2 million in the previous year.
Total standalone income for the full year FY26 was ₹211,739.7 million versus ₹233,565.4 million in FY25.
👀 What to Watch
Investors should exercise caution as standalone profits and revenues show a significant year-on-year decline; it is critical to review the consolidated results for the full global performance impact. The ₹5 dividend provides some yield support, but the underlying growth trajectory requires further scrutiny.
Sun Pharma Appoints R&D Veteran Dr. Andreas Busch as Independent Director for 5-Year Term
Sun Pharmaceutical Industries has appointed Dr. Andreas Busch as an Independent Director for a five-year term starting May 12, 2026. Dr. Busch is a global leader in drug discovery with experience at Sanofi, Bayer, and Shire, having led over 15 drugs to FDA approval. Concurrently, Ms. Satyavati Berera joins the Audit and Risk Management Committees, while Ms. Rama Bijapurkar will retire on May 20, 2026. These appointments significantly strengthen the board's technical expertise and governance framework.
Key Highlights
Dr. Andreas Busch appointed as Independent Director for a 5-year term effective May 12, 2026.
Dr. Busch has a track record of leading over 15 commercial drugs from discovery to FDA approval.
Ms. Satyavati Berera inducted into the Audit Committee and Risk Management Committee.
Ms. Rama Bijapurkar to retire from the Board on May 20, 2026, following the completion of her term.
👀 What to Watch
Investors should view the addition of a world-renowned R&D expert to the board as a positive signal for Sun Pharma's long-term innovation pipeline. No immediate portfolio changes are necessary based on this governance update.
Sun Pharma Ratings Reaffirmed at AAA; CRISIL Places Long-term Rating on Watch
CRISIL and ICRA have reaffirmed Sun Pharma's highest credit ratings of 'AAA' for long-term and 'A1+' for short-term facilities. CRISIL has placed the long-term rating on 'Rating Watch with Developing Implications' following the company's April 27, 2026, announcement to acquire Organon & Co. ICRA, however, has maintained its 'Stable' outlook while reaffirming the ratings. This indicates a period of assessment for the company's capital structure following the significant acquisition.
Key Highlights
CRISIL reaffirmed long-term bank facilities at 'CRISIL AAA' and short-term facilities at 'CRISIL A1+'
ICRA reaffirmed long-term rating at '[ICRA]AAA(Stable)' and short-term rating at '[ICRA]A1+'
CRISIL placed the 'CRISIL AAA' rating on 'Rating Watch with Developing Implications' following the Organon & Co. acquisition
The rating watch follows the definitive agreement signed on April 27, 2026, to acquire Organon & Co.
👀 What to Watch
Investors should monitor the final rating action from CRISIL once the Organon & Co. acquisition is completed to understand the impact on debt levels. The reaffirmation of AAA ratings suggests the company maintains a very strong credit profile despite the expansion.
Sun Pharma Announces Strategic Acquisition of Organon to Scale Global Innovation and Biosimilars
Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon & Company, a move comparable in scale to the historic Ranbaxy acquisition. Organon brings a stable 30% EBITDA margin and approximately $1 billion in annual free cash flow, providing Sun with a leading global position in Women's Health and a robust entry into the biosimilars market. The combined entity will see its innovative medicine revenue share rise to 27%, while established brands will account for 51% of total revenue. To fund the transaction, Sun Pharma will shift from a net-cash position to a Net Debt/EBITDA ratio of approximately 2.3x.
Key Highlights
Acquisition adds a global portfolio with 30% EBITDA margins and $1 billion in annual free cash flow.
Combined innovative medicine revenue to reach 27% of total sales, up from Sun's current 20%.
Entry into the biosimilar market with Organon's $700 million business growing at a 13% CAGR.
Post-acquisition leverage expected at 2.3x Net Debt/EBITDA, with management focused on rapid deleveraging.
Organon provides a massive global footprint in 140 countries and a top-3 position in the $35 billion Women's Health market.
👀 What to Watch
Investors should view this as a transformative growth catalyst that significantly diversifies Sun Pharma's revenue streams into high-margin specialty and biosimilar segments. Monitor the company's execution on deleveraging and the integration of Organon's global commercial platform.
Sun Pharma Releases Investor Call Recording for Organon & Co. Acquisition
Sun Pharmaceutical Industries has released the audio recording of its investor call held on April 27, 2026, regarding the acquisition of Organon & Co. The call provides management's perspective on the strategic rationale and financial implications of this major transaction. This disclosure is part of the company's regulatory compliance under SEBI (LODR) Regulations, 2015. Investors can now access the full discussion to evaluate the long-term impact of the acquisition on Sun Pharma's global portfolio.
Key Highlights
Investor call conducted on April 27, 2026, specifically regarding the Organon & Co. acquisition.
Official audio recording link provided for public and institutional review.
Disclosure made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Management commentary available on the strategic fit and growth potential of the acquired entity.
👀 What to Watch
Investors should listen to the recording to understand the acquisition's valuation and its expected contribution to Sun Pharma's specialty or generic segments. Monitor for further updates on regulatory approvals and integration timelines.
Sun Pharma Announces Transformative Acquisition of Organon & Co to Enter Top 25 Global Pharma
Sun Pharma has announced the acquisition of Organon & Co, a move designed to propel the company into the top 25 global pharmaceutical firms. Organon brings a $3 billion+ established brands portfolio and global leadership in Women's Health, including top-3 positions in contraception and fertility. The acquisition is financially accretive, with Organon generating over $1 billion in annual free cash flow and maintaining EBITDA margins above 30%. This deal significantly diversifies Sun Pharma's revenue, with innovative medicines expected to comprise 27% of the combined entity's sales.
Key Highlights
Acquisition of Organon & Co adds a $3B+ portfolio and leadership in Women's Health (Contraception #2, Fertility #3 globally).
Organon delivers strong financial performance with 30%+ EBITDA margins and $1B+ in annual free cash flows.
Sun Pharma enters the high-growth biosimilars market, leapfrogging to a top 10 global position with 8 products in market.
Combined entity revenue mix shifts to 27% Innovative Medicines and 51% Established Brands/Branded Generics.
Sun Pharma maintains a strong balance sheet with $3.1B+ cash as of FY25 to support this transformation.
👀 What to Watch
This is a major strategic milestone that enhances Sun Pharma's global scale and therapeutic reach. Investors should view this as a long-term value creator, while monitoring the final acquisition price and integration execution.
Sun Pharma to Discuss Acquisition of Organon & Co. in Investor Call
Sun Pharmaceutical Industries Limited has scheduled an investor call on April 27, 2026, to discuss the strategic acquisition of Organon & Co. This acquisition represents a significant expansion move for India's largest pharmaceutical company, which already has a presence in over 100 countries. Senior management will provide updates on the asset, which is expected to influence the company's Global Innovative Medicines portfolio that currently accounts for 20% of total sales. Investors are focused on the deal's valuation and its impact on Sun Pharma's specialty generics leadership.
Key Highlights
Investor call scheduled for April 27, 2026, at 08:00 am IST to discuss the Organon & Co. acquisition.
Sun Pharma's Global Innovative Medicines portfolio currently contributes approximately 20% to total company sales.
The acquisition targets Organon & Co., a major global healthcare company, to bolster Sun Pharma's international footprint.
Sun Pharma maintains manufacturing facilities across five continents and serves physicians and consumers in over 100 countries.
👀 What to Watch
Investors should closely monitor the call for details regarding the acquisition cost, debt implications, and synergy targets. This move could be a major catalyst for long-term growth in the specialty medicines segment.
Sun Pharma to Acquire Organon for $11.75 Billion Enterprise Value
Sun Pharma has entered into a definitive agreement to acquire Organon for $14.00 per share in an all-cash deal, valuing the company at an enterprise value of $11.75 billion. This transformative acquisition will create a global pharmaceutical leader with combined revenues of approximately $12.4 billion, placing Sun Pharma among the top 25 global players. The deal provides Sun Pharma with a top-3 global position in Women's Health and a top-10 position in Biosimilars. While the transaction involves taking on debt, the combined entity's EBITDA and cash flow are expected to nearly double, with a projected Net Debt/EBITDA of 2.3x.
Key Highlights
Acquisition of 100% of Organon for $14.00 per share in cash, totaling an EV of $11.75 billion.
Combined entity pro-forma revenue of $12.4 billion with presence in 150 countries.
Organon reported $6.2 billion in revenue and $1.9 billion in Adjusted EBITDA for CY2025.
Strategic entry into Biosimilars and a top-3 global ranking in Women's Health.
Transaction expected to close in early 2027, funded by cash and committed bank financing.
👀 What to Watch
This is a major strategic move that significantly diversifies Sun Pharma's revenue streams and scales its innovative medicine portfolio. Investors should maintain a positive outlook but monitor the regulatory approval timeline and the company's ability to manage the increased leverage post-2027.
Sun Pharma Clarifies $12 Billion Organon Deal Rumors as Speculative
Sun Pharmaceutical Industries Limited has issued a clarification to the BSE and NSE regarding a news report suggesting a $12 billion deal with Organon was in its final stages. The company stated that the information is speculative and that no material event exists which requires disclosure under Regulation 30. This response follows a nearly 4% decline in the company's stock price triggered by the rumor on April 10, 2026. Sun Pharma emphasized its adherence to governance standards and promised to inform exchanges of any actual material developments.
Key Highlights
Sun Pharma denies the rumored $12 billion Organon deal, calling it speculative.
The company confirms no material information currently requires disclosure under Regulation 30.
The clarification was prompted by a nearly 4% drop in share price following the news report.
Management reiterated commitment to high standards of governance and timely disclosures.
👀 What to Watch
Investors should disregard the speculative news regarding the $12 billion acquisition and rely only on official company disclosures. The stock's recent volatility due to this rumor may stabilize following this official denial.
Sun Pharma Partner Philogen Reports Mixed Clinical Trial Results for Fibromun and Nidlegy
Sun Pharma's partner Philogen reported mixed clinical results, with Fibromun failing to meet primary endpoints in Phase II trials for soft tissue sarcoma (94 patients) and glioblastoma (163 patients). Conversely, Nidlegy demonstrated a strong 52.6% complete pathological response in basal cell carcinoma during the Phase II Duncan study. Regulatory progress is evident as the FDA aligned on a US approval pathway for Nidlegy in melanoma, and three new registrational studies are set to launch in Q2 2026. The company is also moving forward with a new Phase III study (FIBROSARC-2) for Fibromun despite the recent setbacks.
Key Highlights
Fibromun Phase II trials in soft tissue sarcoma and glioblastoma failed to meet primary endpoints for PFS and survival.
Nidlegy Phase II Duncan study reported a significant 52.6% complete pathological response in basal cell carcinoma patients.
FDA alignment reached for Nidlegy's US regulatory pathway for melanoma following a March 2026 Type C meeting.
Three new registrational studies for Nidlegy in skin cancer indications are scheduled to begin enrollment in Q2 2026.
A new Phase III registrational study (FIBROSARC-2) for Fibromun is planned to start in Q2 2026 following regulatory advice.
👀 What to Watch
Investors should closely monitor the commencement and data readouts of the Phase III registrational trials for Nidlegy in mid-2026, as these are now the primary value drivers for this segment of the pipeline. While Fibromun faced setbacks, the strong response rates in Nidlegy's skin cancer trials provide a necessary hedge for the R&D portfolio.
Sun Pharma Showcases 14 Dermatology Abstracts at 2026 AAD Meeting
Sun Pharma is presenting 14 abstracts at the 2026 AAD Annual Meeting, highlighting significant clinical progress in its specialty dermatology portfolio. Key data includes 52-week sustained efficacy for ILUMYA in nail psoriasis and rapid hair regrowth results for LEQSELVI within 8 to 12 weeks. Additionally, WINLEVI demonstrated long-term effectiveness in reducing sebum production over a 52-week study. These presentations reinforce Sun Pharma's position in the high-margin specialty medicine segment, a key growth driver for its US business.
Key Highlights
Presenting 14 abstracts across psoriasis, alopecia areata, and acne research at the 2026 AAD Annual Meeting.
ILUMYA Phase 3b study showed sustained efficacy and safety for nail psoriasis over a 52-week period.
LEQSELVI (deuruxolitinib) demonstrated significant scalp hair regrowth as early as Week 8 and Week 12 in pooled Phase 3 trials.
WINLEVI 52-week study reported progressive reduction in facial sebum production and acne severity.
👀 What to Watch
Investors should monitor the commercial uptake of LEQSELVI and ILUMYA as these specialty products are critical for Sun Pharma's margin expansion. The positive clinical data supports the company's long-term growth strategy in the US dermatology market.
Sun Pharma Launches Semaglutide Brands Noveltreat & Sematrinity for Diabetes and Obesity in India
Sun Pharma has entered the high-growth GLP-1 market in India with the launch of semaglutide under two brands: Noveltreat for weight management and Sematrinity for Type 2 diabetes. The products are priced competitively, with weekly therapy costs ranging from ₹750 to ₹2,000, which is significantly lower than innovator brands. This launch targets a massive patient base, including an estimated 101.3 million diabetics and approximately 25% of the Indian population that is overweight. The company is leveraging its manufacturing expertise and a new patient support program to capture market share in the chronic care segment.
Key Highlights
Launched Noveltreat for weight management in 5 dose strengths ranging from 0.25 mg to 2.4 mg
Launched Sematrinity for Type 2 diabetes in 2 dose strengths: 2 mg/1.5 mL and 4 mg/3 mL
Competitive weekly pricing established at ₹900-₹2,000 for Noveltreat and ₹750-₹1,300 for Sematrinity
Targets a massive domestic market of 101.3 million diabetics and a rising obesity rate of 1 in 4 adults
Utilizes advanced pre-filled and multi-dose pen technology manufactured in Europe for better patient compliance
👀 What to Watch
Investors should view this as a significant long-term growth driver given the 'blockbuster' potential of semaglutide and Sun Pharma's aggressive pricing strategy. Monitor market share gains against global innovators and other domestic competitors entering the GLP-1 space.
Sun Pharma Proposes MOA Amendment for Renewable Energy Entry and Director Re-appointment
Sun Pharma has initiated a postal ballot to seek shareholder approval for amending its Memorandum of Association to include power generation, specifically focusing on renewable sources like solar and hydro for captive use. This strategic move is intended to enhance ESG compliance and reduce long-term energy costs by developing internal power projects. Additionally, the company is seeking the re-appointment of Dr. Pawan Goenka as an Independent Director for a second five-year term through May 2031. Shareholders will also vote on the ratification of the cost auditor's remuneration of INR 31.26 lakh for FY 2025-26.
Key Highlights
Proposed amendment to MOA to allow business in power generation including Hydro, Solar, and Nuclear sources for captive consumption.
Re-appointment of Dr. Pawan Goenka as Independent Director for a second term from May 21, 2026, to May 20, 2031.
Ratification of INR 31.26 lakh remuneration for Cost Auditor M/s. Narasimha Murthy & Co for the financial year 2025-26.
E-voting period scheduled from March 19, 2026, to April 17, 2026, with results to be declared by April 20, 2026.
👀 What to Watch
Investors should view the move toward captive renewable energy as a positive step for operational cost efficiency and sustainability. No immediate portfolio changes are required, but eligible shareholders should participate in the e-voting process.
Sun Pharma: US FDA Accepts ILUMYA sBLA for Psoriatic Arthritis; Decision Due Oct 29, 2026
Sun Pharma has received US FDA acceptance for its supplemental Biologics License Application (sBLA) for ILUMYA to treat adults with active psoriatic arthritis. The FDA is expected to provide a decision by October 29, 2026, marking a potential expansion of the drug's indications beyond plaque, scalp, and nail psoriasis. This development is significant as the company's innovative medicines portfolio now accounts for approximately 20% of total sales. With 1 in 3 psoriasis patients developing psoriatic arthritis, this approval could significantly expand the addressable market for one of Sun Pharma's lead specialty products.
Key Highlights
US FDA decision on ILUMYA for psoriatic arthritis expected by October 29, 2026
Innovative medicines portfolio currently contributes approximately 20% to total company sales
ILUMYA has already supported nearly 140,000 patients worldwide across existing indications
Target market includes a significant portion of the 2.4 million Americans living with psoriatic arthritis
Application is supported by 52-week data from the INSPIRE-1 and INSPIRE-2 Phase 3 clinical trials
👀 What to Watch
Investors should view this as a positive step in Sun Pharma's transition toward a specialty-led business model and monitor the PDUFA date in October 2026. Successful approval would likely enhance long-term revenue growth and margins for the US specialty segment.
Sun Pharma FY25 Revenue Reaches Rs 520 Bn; Innovative Portfolio Scales to 20% of Sales
Sun Pharma reported a strong performance for FY25 with total sales reaching Rs 520 billion, supported by a 29% EBITDA margin. The company has successfully transitioned its business mix, with innovative medicines now contributing 20% of total revenue compared to just 7.3% in FY18. Sun Pharma maintains its leadership in the Indian market with an 8.4% market share and is the 13th largest generics player in the US. The company demonstrates high capital efficiency with a 29% ROCE and a 21% CAGR in adjusted net profit over the last 15 years.
Key Highlights
FY25 Revenue stood at Rs 520 billion with a robust EBITDA margin of 29%, leading the top 9 Indian pharma peers.
Innovative medicines revenue share increased significantly to 20% in FY25, driven by brands like Ilumya, Winlevi, and Cequa.
Maintains #1 position in India with 8.4% market share and top rankings across 14 prescriber classes.
Strong financial health with a 22.8% ROE and 29% ROCE, supported by a 24% CAGR in free cash flow since FY10.
Advanced R&D pipeline features Phase 3 trials for Ilumya (Psoriatic Arthritis) and Phase 2 for GL0034 (GLP-1R Agonist) for diabetes.
👀 What to Watch
Investors should focus on the company's successful pivot toward high-margin specialty and innovative medicines which mitigates generic pricing pressure. The stock remains a strong long-term play given its market leadership in India and improving return ratios.
